Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
DR Tompa, A Immanuel, S Srikanth… - International journal of …, 2021 - Elsevier
The infectious microscopic viruses invade living cells to reproduce themselves, and causes
chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to …
chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to …
The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
KL Seley-Radtke, MK Yates - Antiviral research, 2018 - Elsevier
This is the first of two invited articles reviewing the development of nucleoside-analogue
antiviral drugs, written for a target audience of virologists and other non-chemists, as well as …
antiviral drugs, written for a target audience of virologists and other non-chemists, as well as …
Getting to HBV cure: The promising paths forward
S Fung, HSJ Choi, A Gehring, HLA Janssen - Hepatology, 2022 - Wiley Online Library
Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …
million persons worldwide. Despite the advent of potent antiviral agents that effectively …
Approved antiviral drugs over the past 50 years
E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …
categorized into 13 functional groups have been formally approved for the treatment of the …
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double …
Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …
[HTML][HTML] EASL clinical practice guidelines: management of chronic hepatitis B virus infection
European Association For The Study Of The Liver - Journal of hepatology, 2012 - Elsevier
Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …
for therapy of the resultant disease is continuously improving. New data have become …
[HTML][HTML] Guideline of prevention and treatment for chronic hepatitis B (2015 update)
J Hou, G Wang, F Wang, J Cheng, H Ren… - Journal of clinical and …, 2017 - ncbi.nlm.nih.gov
The Chinese Society of Hepatology, Chinese Medical Association (CMA) and the Society of
Infectious Diseases, CMA organized relevant native experts to establish this Guideline of …
Infectious Diseases, CMA organized relevant native experts to establish this Guideline of …
Hepatitis B virus infection
YF Liaw, CM Chu - The lancet, 2009 - thelancet.com
Since the introduction of the hepatitis B vaccine and other preventive measures, the
worldwide prevalence of hepatitis B infection has fallen. However, chronic infection remains …
worldwide prevalence of hepatitis B infection has fallen. However, chronic infection remains …
Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities
The host immune system plays an important role in chronic hepatitis B (CHB), both in viral
clearance and hepatocellular damage. Advances in our understanding of the natural history …
clearance and hepatocellular damage. Advances in our understanding of the natural history …